<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:department>Biology</gtr:department><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:line4>Swindon</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SN2 1ET</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AAB72550-73A0-49F5-8F28-4D5400A221FF"><gtr:id>AAB72550-73A0-49F5-8F28-4D5400A221FF</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>White</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A9A0759F-D5BA-432F-BFCD-25983322CBDF"><gtr:id>A9A0759F-D5BA-432F-BFCD-25983322CBDF</gtr:id><gtr:firstName>Nia</gtr:firstName><gtr:surname>Bryant</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4BE01856-256E-4C96-904F-0088DEA339E9"><gtr:id>4BE01856-256E-4C96-904F-0088DEA339E9</gtr:id><gtr:firstName>Daniel</gtr:firstName><gtr:surname>Ungar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FM018237%2F1"><gtr:id>7ACFBF0B-F219-4B01-9A8A-57727FC38F93</gtr:id><gtr:title>A Combinatorial Approach to Enhance Production of Monoclonal Antibodies</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/M018237/1</gtr:grantReference><gtr:abstractText>Biopharmaceuticals, also known as biologic medical products (biologics for short) are medicinal products manufactured in or extracted from biological systems and are distinct from synthesized pharmaceutical products. Examples include vaccines against diseases such as polio and therapeutics used to treat numerous diseases, such as cancer and arthritis. These therapeutics are often molecules called monoclonal antibodies that are made by the immune system, our inbuilt anti-disease defense mechanism. Perhaps one the best known examples of this is Trastuzumab (trade name; Herceptin), a monoclonal antibody that is used to treat certain breast cancers. Production of these biologics is expensive and this translates into a high financial cost to health care providers.

This project aims to alter the cells that make monoclonal antibodies for therapeutic use, so that they make larger amounts with reduced production costs. This should increase the availability of these powerful therapeutics.</gtr:abstractText><gtr:technicalSummary>CHO cells are the most widely used industrial system for producing recombinant therapeutic proteins, but can struggle to express and secrete large biologics such as monoclonal antibodies (mAbs) at sustained high levels. We will address this with a systematic programme of synthetic cell bioengineering that combines innovative approaches to concomitantly increase CHO cells' capacities to express and secrete mAbs. Our team combines complementary skill sets to enhance successive steps that are potentially rate-limiting for mAb production, including transgene expression, mRNA translation, intracellular trafficking, post-translational modification and secretion. We will combine a series of novel improvements in a holistic manner to generate CHO cell lines optimised to produce mAbs of great economic and therapeutic value. In so doing, the project will establish a robust, flexible and adaptable UK platform for optimisation and manufacture of therapeutic biologics.</gtr:technicalSummary><gtr:potentialImpactText>As described in proposal submitted to TSB</gtr:potentialImpactText><gtr:fund><gtr:end>2020-07-06</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2015-07-07</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2738492</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Disclosure relates to recombinant protein expression systems comprising genetically modified cells wherein the cells are transformed or transfected with tRNA genes to reduce base mismatch due to genetic degeneracy in the genetic code and hence reliance on wobble for decoding; the modified cells have so improved recombinant protein expression.</gtr:description><gtr:id>BCA32E86-EEFD-47B0-8E37-2EF2E28A422A</gtr:id><gtr:impact>Collaborations with industrial partners.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>PCT/GB2017?050028</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Recombinant protein production</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Novel CHO cell lines have been constructed that carry transgenes intended to enhance expression of therapeutic antibodies.</gtr:description><gtr:id>7BF8FC8D-7840-4036-B921-38E741DD8482</gtr:id><gtr:impact>Patent filed. 

Collaborations underway with industrial partners.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Transgenic CHO lines</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BB/M018237/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>17F21DBC-4946-4262-AD07-9914F6EA12F7</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Bioengineering</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>A442BF36-F335-483E-9282-F3BB48AC2C47</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Cell biology</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>FB535BD0-E265-4C0A-8532-32DCB83A3951</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Tools, technologies &amp; methods</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>18D298A9-FFE3-432F-B077-E3B703272E29</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biochemical engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>0CB3E3B8-1C4E-4DEB-89C2-D9CDF3586F5E</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Novel industrial products</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>7DA052B9-38AC-4F23-88FA-66C8DEB08B81</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Organelles &amp; components</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>11093A5C-4232-4625-96BA-FC7E5BA96CE2</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Protein engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>3493671D-A4CF-4197-90A7-3CCFBE1C0627</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Tools for the biosciences</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>